Erythropoiesis stimulating agents, thrombosis and cancer

Radiotherapy and Oncology

Volumn 95, Issue 3, 2010, Pages 269-276

  Barbera, Lisa ^a,c   Thomas, Gillian ^a,b,c  

^a

^b UNIVERSITY OF TORONTO   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Angiogenesis; Erythropoiesis stimulating agents; Thrombosis

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; ERYTHROPOIETIN RECEPTOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NIMORAZOLE; PLACEBO;

ADVANCED CANCER; ANEMIA; BLOOD CLOTTING; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE ASSOCIATION; HEAD AND NECK CANCER; HUMAN; NEOPLASM; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; TUMOR GROWTH; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD COAGULATION; HEMATINICS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; THROMBOPLASTIN; THROMBOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENOUS THROMBOEMBOLISM;

EID: 77952582859     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2010.02.008     Document Type: Review

References (125)

1. Grogan M., Thomas G.M., Melamed I., et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86 (1999) 1528-1536
2. Winter W.E., Maxwel G.L., Tian C., et al. Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a gynecologic oncology group study. Gynecol Oncol 94 (2004) 495-501
3. Los Santos J.F., and Thomas G.M. Anemia correction in malignancy management: threat or opportunity?. Gynecol Oncol 105 (2007) 517-529
4. Bohlius J., Wilson J., Seidenfeld J., et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98 (2006) 708-714
5. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
6. Leyland-Jones B., Semiglazov V., Pawlicki M., et al. Maintaining normal hemoglobin levels with epoetin alpha in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23 (2005) 5960-5972
7. Wright J.R., Ung Y.C., Julian J.A., et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol (2007)
8. Thomas G.M., Ali S., Hoebers F.J.P., et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 108 (2008) 317-325
9. Sorensen H.T., Mellemkjaer L., Steffensen F.H., Olsen J.H., and Nielsen G.L. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Eng J Med 338 (1998) 1169-1173
10. Kearon C. Natural history of venous thromboembolism. Circulation 107 (2003) I22-I30
11. Kroger K., Weiland D., Ose C., et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 17 (2006) 297-303
12. Morgan M.A., Iyengar T.D., Napiorkowski B.E., Rubin S.C., and Mikuta J.J. The clinical course of deep vein thrombosis in patients with gynecologic cancer. Gynecol Oncol 84 (2002) 67-71
13. Lin J., Wakefield T.W., and Henke P.K. Risk factors associated with venous thromboembolic events in patients with malignancy. Blood Coagul Fibrinolysis 17 (2006) 265-270
14. Henke M., Mattern D., Pepe M., et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J Clin Oncol 24 (2006) 4708-4713
15. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 50 (2004) 187-196
16. Gouin-Thibault I., Achkar A., and Samama M.M. The thrombophilic state in cancer patients. Acta Haematol 106 (2001) 33-42
17. Goldenberg N., Kahn S.R., and Solymoss S. Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism. J Clin Oncol 21 (2003) 4194-4199
18. Kakkar A.K., DeRuvo N., Chinswangwatanakul V., Tebbutt S., and Williamson R.C. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 346 (1995) 1004-1005
19. Silverstein M.D., Heit J.A., Mohr D.N., Petterson T.M., O'Fallon W.M., and Melton III L.J. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158 (1998) 585-593
20. Heit J.A., O'Fallon W.M., Petterson T.M., et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162 (2002) 1245-1248
21. Samama M.M. For the sirius study group. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the sirius study. Arch Intern Med 160 (2000) 3415-3420
22. Samama M.M., Dahl O.E., Quinlan D.J., Mismetti P., and Rosencher N. Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haematologica 88 (2003) 1410-1421
23. Alikhan R., Cohen A.T., Combe S., et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX study. Arch Intern Med 164 (2004) 963-968
24. Verso M., and Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21 (2003) 3665-3675
25. Heit J.A. Cancer and venous thromboembolism: scope of the problem. Cancer Control 12 (2005) 5-10
26. Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., O'Fallon W.M., and Melton III L.J. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160 (2000) 809-815
27. Rickles F.R., and Levine M.N. Venous thromboembolism in malignancy and malignancy in venous thromboembolism. Haemostasis 28 (1998) 43-49
28. Brandes A.A., Scelzi E., Salmistraro G., et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer 33 (1997) 1592-1596
29. Deitcher S.R., and Gomes M.P. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer 101 (2004) 439-449
30. Prandoni P., Falanga A., and Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 6 (2005) 401-410
31. Gordon S.G., and Cross B.A. A factor X-activating cysteine protease from malignant tissue. J Clin Invest 67 (1981) 1665-1671
32. Lip G.Y., Chin B.S., and Blann A.D. Cancer and the prothrombotic state. Lancet Oncol 3 (2002) 27-34
33. Lee A.Y. Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treat Rev 28 (2002) 137-140
34. Donati M.B., Falanga A., Consonni R., et al. Cancer procoagulant in acute non lymphoid leukemia: relationship of enzyme detection to disease activity. Thromb Haemost 64 (1990) 11-16
35. Pineo G.F., Brain M.C., Gallus A.S., Hirsh J., Hatton M.W., and Regoeczi E. Tumors, mucus production, and hypercoagulability. Ann N Y Acad Sci 230 (1974) 262-270
36. Varon D., and Brill A. Platelets cross-talk with tumor cells. Haemostasis 31 (2001) 64-66
37. Balkwill F., Osborne R., Burke F., et al. Evidence for tumour necrosis factor/cachectin production in cancer. Lancet 2 (1987) 1229-1232
38. Grignani G., and Maiolo A. Cytokines and hemostasis. Haematologica 85 (2000) 967-972
39. van Hinsbergh V.W., Bauer K.A., Kooistra T., et al. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood 76 (1990) 2284-2289
40. Kwaan H.C. The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 11 (1992) 291-311
41. Rickles F.R., Patierno S., and Fernandez P.M. Tissue factor, thrombin, and cancer. Chest 124 (2003) 58S-68S
42. Shoji M., Abe K., Nawroth P.P., and Rickles F.R. Molecular mechanisms linking thrombosis and angiogenesis in cancer. Trends Cardiovasc Med 7 (1997) 52-59
43. Versteeg H.H., Peppelenbosch M.P., and Spek C.A. Tissue factor signal transduction in angiogenesis. Carcinogenesis 24 (2003) 1009-1013
44. Fernandez P.M., and Rickles F.R. Tissue factor and angiogenesis in cancer. Curr Opin Hematol 9 (2002) 401-406
45. Hejna M., Raderer M., and Zielinski C.C. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 91 (1999) 22-36
46. Wang X., Fu S., Freedman R.S., and Kavanagh J.J. Venous thromboembolism syndrome in gynecological cancer. Int J Gynecol Cancer 16 (2006) 458-471
47. Winter P.C. The pathogenesis of venous thromboembolism in cancer: emerging links with tumour biology. Hematol Oncol 24 (2006) 126-133
48. Abe K., Shoji M., Chen J., et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 96 (1999) 8663-8668
49. Rao L.V., and Pendurthi U.R. Factor VIIIa-induced gene expression: potential implications in pathophysiology. Trends Cardiovasc Med 11 (2001) 14-21
50. Zhang Y., Deng Y., Luther T., et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 94 (1994) 1320-1327
51. Maragoudakis M.E., Tsopanoglou N.E., Andriopoulou P., and Maragoudakis M.M. Effects of thrombin/thrombosis in angiogenesis and tumour progression. Matrix Biol 19 (2000) 345-351
52. Carmeliet P. Biomedicine. Clotting factors build blood vessels. Science 293 (2001) 1602-1604
53. Rickles F.R., and Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 102 (2001) V215-V224
54. Abdulkadir S.A., Carvalhal G.F., Kaleem Z., et al. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 31 (2000) 443-447
55. Kakkar A.K., Chinswangwatanakul V., Lemoine N.R., Tebbutt S., and Williamson R.C. Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma. Br J Surg 86 (1999) 890-894
56. Mueller B.M., Reisfeld R.A., Edgington T.S., and Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 89 (1992) 11832-11836
57. Dvorak H.F., Harvey V.S., Estrella P., Brown L.F., McDonagh J., and Dvorak A.M. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest 57 (1987) 673-686
58. van Hinsbergh V.W., Koolwijk P., and Hanemaaijer R. Role of fibrin and plasminogen activators in repair-associated angiogenesis: in vitro studies with human endothelial cells. EXS 79 (1997) 391-411
59. Belting M., Dorrell M.I., Sandgren S., et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 10 (2004) 502-509
60. Yin Y.J., Salah Z., Grisaru-Granovsky S., et al. Human protease-activated receptor 1 expression in malignant epithelia: a role in invasiveness. Arterioscler Thromb Vasc Biol 23 (2003) 940-944
61. Even-Ram S., Uziely B., Cohen P., et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 4 (1998) 909-914
62. Mechtcheriakova D., Wlachos A., Holzmuller H., Binder B.R., and Hofer E. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 93 (1999) 3811-3823
63. Clauss M., Gerlach M., Gerlach H., et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172 (1990) 1535-1545
64. Calnek D.S., and Grinnell B.W. Thrombomodulin-dependent anticoagulant activity is regulated by vascular endothelial growth factor. Exp Cell Res 238 (1998) 294-298
65. Kroon M.E., Koolwijk P., Vermeer M.A., van der Vecht B., and van Hinsbergh V.W. Vascular endothelial growth factor enhances the expression of urokinase receptor in human endothelial cells via protein kinase C activation. Thromb Haemost 85 (2001) 296-302
66. Pepper M.S., Ferrara N., Orci L., and Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 181 (1991) 902-906
67. Mandriota S.J., and Pepper M.S. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J Cell Sci 110 (1997) 2293-2302
68. Carroll V.A., and Binder B.R. The role of the plasminogen activation system in cancer. Semin Thromb Hemost 25 (1999) 183-197
69. Yan S.F., Mackman N., Kisiel W., Stern D.M., and Pinsky D.J. Hypoxia/hypoxemia-induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. Arterioscler Thromb Vasc Biol 19 (1999) 2029-2035
70. Hockel M., Vorndran B., Schlenger K., Baussmann E., and Knapstein P.G. Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol Oncol 51 (1993) 141-149
71. Brat D.J., and Van Meir E.G. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 84 (2004) 397-405
72. Lawson C.A., Yan S.D., Yan S.F., et al. Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. J Clin Invest 99 (1997) 1729-1738
73. Amirkhosravi A., Meyer T., Warnes G., et al. Pentoxifylline inhibits hypoxia-induced upregulation of tumor cell tissue factor and vascular endothelial growth factor. Thromb Haemost 80 (1998) 598-602
74. Rong Y., Durden D.L., Van Meir E.G., and Brat D.J. 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 65 (2006) 529-539
75. von Tempelhoff G.F., Nieman F., Heilmann L., and Hommel G. Association between blood rheology, thrombosis and cancer survival in patients with gynecologic malignancy. Clin Hemorheol Microcirc 22 (2000) 107-130
76. Kakkar A.K., Levine M.N., Kadziola Z., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22 (2004) 1944-1948
77. Lee A.Y., Rickles F.R., Julian J.A., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23 (2005) 2123-2129
78. Klerk C.P., Smorenburg S.M., Otten H.M., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23 (2005) 2130-2135
79. Altinbas M., Coskun H.S., Er O., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2 (2004) 1266-1271
80. Zacharski L.R., Henderson W.G., Rickles F.R., et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 53 (1984) 2046-2052
81. Norrby K. Low-molecular-weight heparins and angiogenesis. APMIS 114 (2006) 79-102
82. Smorenburg S.M., and Van Noorden C.J. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 53 (2001) 93-105
83. Collen A., Smorenburg S.M., Peters E., et al. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 60 (2000) 6196-6200
84. Amirkhosravi A., Mousa S.A., Amaya M., and Francis J.L. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost 1 (2003) 1972-1976
85. Bohlius J., Wilson J., Seidenfeld J., et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 3 (2006) CD003407
86. Amgen. Results from a phase 3, randomized, double-blind, placebo-controlled study of darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy. ClinicalStudyResults.org. http://www.clinicalstudyresults.org/documents/company-study_2157_0.pdf [accessed 12.03.07].
87. Overgaard J. Interim analysis of DAHANCA 10. Danish head and neck cancer group. http://conman.au.dk/dahanca/get_media_file.php?mediaid=125 [accessed 20.02.07].
88. Thomas G., Ali S., Hoebers F.J.P., et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 120 g/dL with erythropoietin vs above 100 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 108 (2008) 317-325
89. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Eng J Med 355 (2006) 2085-2098
90. Wun T., Law L., Harvey D., Sieracki B., Scudder S.A., and Ryu J.K. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 98 (2003) 1514-1520
91. Barbui T., Finazzi G., Grassi A., and Marchioli R. Thrombosis in cancer patients treated with hematopoietic growth factors - a meta-analysis. On behalf of the subcommittee on haemostasis and malignancy of the scientific and standardization committee of the ISTH. Thromb Haemost 75 (1996) 368-371
92. Khorana A.A., Francis C.W., Culakova E., and Lyman G.H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104 (2005) 2822-2829
93. Barbera L., and Thomas G. Venous thromboembolism in cervical cancer. Lancet Oncol 9 (2008) 54-60
94. Bohlius J., Schmidlin K., Brillant C., et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373 (2009) 1532-1542
95. Vaupel P., and Mayer A. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 363 (2004) 992
96. Gemici C. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 363 (2004) 992-993
97. Kaanders J.H., and Van der Kogel A.J. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 363 (2004) 78-79
98. Haddad R., and Posner M. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 363 (2004) 79-80
99. Leyland-Jones B., and Mahmud S. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 363 (2004) 80
100. Steensma D.P., and Loprinzi C.L. Erythropoietin use in cancer patients: a matter of life and death?. J Clin Oncol 23 (2005) 5865-5868
101. Overgaard J., Hoff C., Sand Hansenm H., et al. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp(R)) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) - the Danish head and neck cancer group DAHANCA 10. Eur J Cancer Suppl 5 (2007) 7
102. Cage S. UPDATE 3-Roche suspends enrollment in anemia drug trial.Reuters. http://today.reuters.com/news/articlebusiness.aspx?type=BIOTRX&storyID=2007-02-23T200859Z_01_L23289332_RTRIDST_0_ROCHE-CERA-UPDATE-3.XML&from=business [accessed 7.03.07].
103. Machtay M., Pajak T.F., Suntharalingam M., et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the radiation therapy oncology group (RTOG 99-03). Int J Radiat Oncol Biol Phys 69 (2007) 1008-1017
104. FDA Strengthens Safety Information for Erythropoiesis-Stimulating Agents (ESAs). US Food and Drug Administration. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01582.html [accessed 9.03.07].
105. Eurpoean Medicines Agency. PRESS RELEASE: EMEA recommends a new warning for epoetins for their use in cancer patients.Doc.Ref.EMEA/CHMP/333963/2008 -corr.*. http://www.emea.europa.eu/pdfs/human/press/pr/33396308en.pdf [accessed 2.09.09].
106. Solar P., Feldman L., Jeong J.Y., Busingye J.R., and Sytkowski A.J. Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype. Int J Cancer 122 (2008) 281-288
107. Farrell F., and Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9 (2004) 18-30
108. Acs G., Acs P., Beckwith S.M., et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61 (2001) 3561-3565
109. Dagnon K., Pacary E., Commo F., et al. Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res 11 (2005) 993-999
110. Leo C., Horn L.C., Rauscher C., et al. Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis. Clin Cancer Res 12 (2006) 6894-6900
111. Fandrey J. Erythropoietin receptors on tumor cells: what do they mean?. Oncologist 13 (2008) 16-20
112. Brown W.M., Maxwell P., Graham A.N., et al. Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells 25 (2007) 718-722
113. Osterborg A., Aapro M., Cornes P., Haselbeck A., Hayward C.R., and Jelkmann W. Preclinical studies of erythropoietin receptor expression in tumour cells: Impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 43 (2007) 510-519
114. Sinclair A.M., Todd M.D., Forsythe K., Knox S.J., Elliott S., and Begley C.G. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 110 (2007) 477-488
115. Acs G., Zhang P.J., McGrath C.M., et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 162 (2003) 1789-1806
116. Malyszko J., Malyszko J.S., Borawski J., et al. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy. Thromb Res 77 (1995) 133-143
117. Fuste B., Serradell M., Escolar G., et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 88 (2002) 678-685
118. Stasko J., Drouet L., Soria C., Mazoyer E., Caen J., and Kubisz P. Erythropoietin and granulocyte colony-stimulating factor increase plasminogen activator inhibitor-1 release in HUVEC culture. Thromb Res 105 (2002) 161-164
119. Hazelbag S., Kenter G.G., Gorter A., and Fleuren G.J. Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer. Int J Cancer 112 (2004) 1020-1028
120. Stohlawetz P.J., Dzirlo L., Hergovich N., et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 95 (2000) 2983-2989
121. Kertesz N., Wu J., Chen T.H., Sucov H.M., and Wu H. The role of erythropoietin in regulating angiogenesis. Dev Biol 276 (2004) 101-110
122. Watanabe D., Suzuma K., Matsui S., et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Eng J Med 353 (2005) 782-792
123. Hardee M.E., Cao Y., Fu P., et al. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE. 2 (2007) e549
124. Yasuda Y., Fujita Y., Matsuo T., et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24 (2003) 1021-1029
125. Heeschen C., Aicher A., Lehmann R., et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102 (2003) 1340-1346